Corbus Shares Advance as Pipeline Progress Takes Center Stage

Corbus Pharmaceuticals shares edged higher in after-hours trading, reaching $9.93 after closing at $9.74—a gain of nearly 2 percent. Investor attention remains fixed on the company’s latest quarterly results and, more significantly, advancements within its clinical development pipeline.

Strong Cash Position Supports Ambitious Plans

The biotechnology firm reported a second-quarter 2025 net loss of $17.7 million, a figure that exceeded analyst expectations. Operating expenses climbed to $19.2 million, primarily driven by increased clinical development activities.

Despite these losses, Corbus maintains a substantial financial cushion. With $116.6 million in cash and investments, the company is funded through the second quarter of 2027. This robust capital position provides significant runway for its ambitious research and development initiatives.

Key Upcoming Catalysts in Oncology Programs

Two promising oncology candidates are drawing particular interest from investors:

Should investors sell immediately? Or is it worth buying Corbus?

• CRB-701: This Nectin-4-targeting antibody-drug conjugate (ADC) is scheduled to present updated Phase 1/2 data at the ESMO 2025 conference in October. The FDA has already granted it Fast Track designation for recurrent cervical cancer. Corbus anticipates completing dose optimization for this candidate during the fourth quarter.
• CRB-601: The company expects to report initial data from the Phase 1 dose escalation study for this anti-integrin antibody before the end of the current year.

Corbus is currently evaluating two dosage levels of CRB-701 (2.7 mg/kg and 3.6 mg/kg) across multiple tumor types, including head and neck cancers and bladder cancer.

Obesity Treatment Candidate Advances

In parallel, Corbus is making progress with CRB-913, its candidate for obesity treatment. The company has initiated the multiple ascending dose (MAD) phase of its study, with initial data expected in the second half of 2025. A Phase 1b study involving obese, non-diabetic subjects is also slated to begin in the fourth quarter.

Preclinical data suggests CRB-913 may be more peripherally restricted than older compounds, potentially reducing central nervous system-related side effects.

Analysts Maintain Bullish Price Targets

Despite recent quarterly losses, market analysts remain optimistic about Corbus’s prospects. The average price target stands at $53.22, implying substantial upside potential from current trading levels. The overwhelming majority of covering analysts continue to recommend the stock as a buy.